Find the Perfect Plan for Your Investment Journey
Last Price
52 Week Range
$200.08 - $377.46
Next Earnings Date
Aug 05 2025 (Estimate)
Next Earnings Date
Aug 05 2025 (Est.)
Last Price
Market Cap | $7.24B |
EV | $6.51B |
Shares Outstanding | 23.17M |
Beta | -0.92 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $414.07 |
P/E 2025E | - |
P/Revenue 2025E | 10.88x |
Revenue | - |
EPS | -14.40% |
Operating Cash Flow | -35.30% |
Free Cash Flow | -23.60% |
Revenue | 112.20% |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | 95.40% |
Net Profit Margin 2025E | -40.71% |
ROE 2025E | -73.19% |
ROCE 2024 | -80.35% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Madrigal Pharmaceuticals, Inc.
MDGL
Sector
Healthcare
Industry
Biotechnology
CEO
Sibold, William
Employees
528
Website
www.madrigalpharma.comIPO Date
2007-02-06
Headquarters
Four Tower Bridge, Suite 200, 200 Barr Harbor Drive, West Conshohocken, Pennsylvania, 19428, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved